Single-fraction stereotactic radiosurgery versus microsurgical resection for the treatment of vestibular schwannoma: a systematic review and meta-analysis.
Benefit assessment
Radiosurgery
Systematic review
Vestibular schwannoma
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
12 Dec 2022
12 Dec 2022
Historique:
received:
28
12
2021
accepted:
03
11
2022
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
15
12
2022
Statut:
epublish
Résumé
Vestibular schwannomas are benign tumours for which various treatments are available. We performed a systematic review of prospective controlled trials comparing the patient-relevant benefits and harms of single-fraction stereotactic radiosurgery (sfSRS) with microsurgical resection (MR) in patients with vestibular schwannoma. We searched for randomized controlled trials (RCTs) and non-randomized prospective controlled trials in MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and study registries (last search: 09/2021) and also screened reference lists of relevant systematic reviews. Manufacturers were asked to provide unpublished data. Eligible studies investigated at least one patient-relevant outcome. We assessed the risk of bias (high or low) at the study and outcome level. If feasible, meta-analyses were performed. We graded the results into different categories (hint, indication, or proof of greater benefit or harm). We identified three non-randomized prospective controlled trials of generally low quality with evaluable data on 339 patients with unilateral vestibular schwannoma. There was an indication of greater benefit of sfSRS compared with MR for facial palsy (OR 0.06, 95% CI 0.02-0.21, p < 0.001, 2 studies), hearing function (no pooled estimate available, 2 studies), and length of hospital stay (no pooled estimate available, 2 studies). We found no clinically relevant differences for mortality, vertigo, headaches, tinnitus, balance function, work disability, adverse events, and health-related quality of life. Our systematic review indicates that sfSRS has greater benefits than MR in patients with unilateral vestibular schwannoma. However, it is unclear whether this conclusion still holds after 2 years, as long-term studies are lacking. It is also unclear whether the effects of sfSRS are similar in patients with bilateral vestibular schwannomas. Long-term prospective studies including patients with this condition would therefore be useful. The full (German language) protocol and report (Commission No. N20-03) are available on the institute's website: www.iqwig.de/en/projects/n20-03.html.
Sections du résumé
BACKGROUND
BACKGROUND
Vestibular schwannomas are benign tumours for which various treatments are available. We performed a systematic review of prospective controlled trials comparing the patient-relevant benefits and harms of single-fraction stereotactic radiosurgery (sfSRS) with microsurgical resection (MR) in patients with vestibular schwannoma.
METHODS
METHODS
We searched for randomized controlled trials (RCTs) and non-randomized prospective controlled trials in MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and study registries (last search: 09/2021) and also screened reference lists of relevant systematic reviews. Manufacturers were asked to provide unpublished data. Eligible studies investigated at least one patient-relevant outcome. We assessed the risk of bias (high or low) at the study and outcome level. If feasible, meta-analyses were performed. We graded the results into different categories (hint, indication, or proof of greater benefit or harm).
RESULTS
RESULTS
We identified three non-randomized prospective controlled trials of generally low quality with evaluable data on 339 patients with unilateral vestibular schwannoma. There was an indication of greater benefit of sfSRS compared with MR for facial palsy (OR 0.06, 95% CI 0.02-0.21, p < 0.001, 2 studies), hearing function (no pooled estimate available, 2 studies), and length of hospital stay (no pooled estimate available, 2 studies). We found no clinically relevant differences for mortality, vertigo, headaches, tinnitus, balance function, work disability, adverse events, and health-related quality of life.
CONCLUSIONS
CONCLUSIONS
Our systematic review indicates that sfSRS has greater benefits than MR in patients with unilateral vestibular schwannoma. However, it is unclear whether this conclusion still holds after 2 years, as long-term studies are lacking. It is also unclear whether the effects of sfSRS are similar in patients with bilateral vestibular schwannomas. Long-term prospective studies including patients with this condition would therefore be useful.
SYSTEMATIC REVIEW REGISTRATION
BACKGROUND
The full (German language) protocol and report (Commission No. N20-03) are available on the institute's website: www.iqwig.de/en/projects/n20-03.html.
Identifiants
pubmed: 36503553
doi: 10.1186/s13643-022-02118-9
pii: 10.1186/s13643-022-02118-9
pmc: PMC9743510
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
265Informations de copyright
© 2022. The Author(s).
Références
Clin Pharmacol Ther. 2001 Mar;69(3):89-95
pubmed: 11240971
Neurosurgery. 2009 Apr;64(4):654-61; discussion 661-3
pubmed: 19197222
Otolaryngol Head Neck Surg. 2021 Sep;165(3):458-464
pubmed: 33494647
Neurosurgery. 2018 Feb 1;82(2):E35-E39
pubmed: 29309683
BMJ Open. 2013 Feb 22;3(2):
pubmed: 23435793
Cochrane Database Syst Rev. 2014 Dec 16;(12):CD009897
pubmed: 25511415
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
Front Neurol. 2011 Aug 30;2:55
pubmed: 21941519
Neurosurgery. 2006 Jul;59(1):77-85; discussion 77-85
pubmed: 16823303
J Clin Neurosci. 2018 Jun;52:26-31
pubmed: 29656878
World Neurosurg. 2015 Aug;84(2):283-291.e1
pubmed: 25790873
Neuro Oncol. 2020 Jan 11;22(1):31-45
pubmed: 31504802
Neurosurgery. 2018 Feb 1;82(2):E49-E51
pubmed: 29309637
J Neurosurg. 2009 Oct;111(4):855-62
pubmed: 19301957
Neurosurgery. 2018 Feb 1;82(2):E40-E43
pubmed: 29309632
Otol Neurotol. 2020 Sep;41(8):1122-1130
pubmed: 32569150
BMJ. 2004 Jun 19;328(7454):1490
pubmed: 15205295
Otol Neurotol. 2021 Feb 1;42(2):e199-e208
pubmed: 33177408
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551